Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women

Article Abstract:

Estrogen replacement therapy may not lower the risk of heart attack or death in postmenopausal women with coronary heart disease. Researchers randomly assigned 2,763 postmenopausal women with coronary disease to take estrogen plus medroxyprogesterone acetate or a placebo daily. After an average follow-up of 4.1 years, the rate of heart attack or death from coronary heart disease was similar in both groups. This occurred despite the fact that the women on hormone therapy had lower levels of LDL, or 'bad' cholesterol and higher levels of HDL, or 'good' cholesterol.

Author: Hulley, Stephen
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women

Article Abstract:

Estrogen replacement therapy may not lower the risk of heart attack or death in postmenopausal women with coronary heart disease. Researchers randomly assigned 2,763 postmenopausal women with coronary disease to take estrogen plus medroxyprogesterone acetate or a placebo daily. After an average follow-up of 4.1 years, the rate of heart attack or death from coronary heart disease was similar in both groups. This occurred despite the fact that the women on hormone therapy had lower levels of LDL, or 'bad' cholesterol and higher levels of HDL, or 'good' cholesterol.

Author: Hulley, Stephen
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: The Heart and Estrogen/Progestin Replacement Study (HERS)

Article Abstract:

Many postmenopausal women are not adequately treated for high cholesterol levels. This was the conclusion of a study that measured blood levels of low-density-lipoprotein (LDL), or 'bad' cholesterol, in 2,763 postmenopausal women who had coronary heart disease. About 90% of the women had LDL cholesterol levels over 100 milligrams per deciliter, which is considered an elevated level according to the National Cholesterol Education Program Adult Treatment Panel. This was true even though many women were taking cholesterol-lowering drugs.

Author: Vittinghoff, Eric, Hulley, Stephen, Herrington, David M., Bittner, Vera, Schrott, Helmut G.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
Care and treatment, Measurement, Physiological aspects, Postmenopausal women, Blood cholesterol, Hypercholesterolemia

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Prevention, Coronary heart disease, Heart attack, Hormone therapy, Estrogen, Estrogens
Similar abstracts:
  • Abstracts: Hormone Replacement Therapy and Heart Disease Prevention. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
  • Abstracts: Expanding the use of thrombolytic therapy for acute myocardial infarction. Treatment-seeking behavior among those with signs and symptoms of acute myocardial infarction
  • Abstracts: Patients attending STD clinics in an evolving health care environment: demographics, insurance coverage, preferences for STD services, and STD morbidity
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.